• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Phase Forward to Acquire Maaguzi for $11M, Profits Down in Q2

Phase Forward to Acquire Maaguzi for $11M, Profits Down in Q2

July 28, 2009
CenterWatch Staff

Within days of announcing the pending acquisition of Covance’s interactive voice and web response business, eClinical company Phase Forward announced Monday it has purchased technology company Maaguzi for $11 million cash.

With operations in Indianapolis, Ind., and Morrisville, N.C., Maaguzi provides electronic patient reported outcomes (ePRO) services to the pharmaceutical industry. The acquisition of Maaguzi's lead technology, OutcomeLogix, facilitates Phase Forward’s entry into the ePRO and observational studies market. Maaguzi’s chief operating officer Scott Dixon will join Phase Forward as vice president of its newly formed Outcome Logix Group.

“We believe our recent acquisitions are critical steps to ensuring that Phase Forward maintains and extends its current leadership position,” Phase Forward chairman and CEO Bob Weiler told investors on a conference call last night.

The Waltham, Mass.-based company also reported financial results for the second quarter of 2009, reflecting a $1.5-million decrease in net income. GAAP net income for the quarter was $2.2 million, or $0.05 per diluted share, compared with $3.7 million, or $0.08 per diluted share in 2008. Q2 revenues were up 29% to $52.5 million, compared with revenues of $40.9 million in the second quarter of 2008.

Phase Forward's shares were down 9% to $14.27 in afternoon trading Tuesday.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing